Sage Journals: Discover world-class research

Abstract

Osteosarcoma (OS), the most common bone tumor, includes OS of the head (OSH) and appendicular OS (OSA). In dogs, it is classified into 6 histologic subtypes: osteoblastic, chondroblastic, fibroblastic, telangiectatic, giant cell, and poorly differentiated. This study investigated the significance of the histologic classification relevant to clinical outcome and the histologic and immunohistochemical relationships between pleomorphism and expression of cytoskeletal proteins in 60 cases each of OSH and OSA. Most neoplasms exhibited histologic diversity, and 64% of OS contained multiple subtypes. In addition to the above 6 subtypes, myxoid, round cell, and epithelioid subtypes were observed. Although the epithelioid subtypes were observed in only OSH, no significant difference in the frequency of other subtypes was observed. Also, no significant relevance was observed between the clinical outcome and histologic subtypes. Cytokeratin (CK) was expressed in both epithelioid and sarcomatoid tumor cells in various subtypes, and all CK-positive tumor cells also expressed vimentin. Vimentin and α-smooth muscle actin (SMA) were expressed in all subtypes. A few SMA-positive spindle-shaped tumor cells exhibited desmin expression. Glial fibrillary acidic protein–positive tumor cells were observed in many subtypes, and some of these cells showed neurofilament expression. Although OSH exhibited significantly stronger immunoreactivity for SMA than OSA, no significant difference in other cytoskeletal proteins was observed. Some tumor cells had cytoskeletal protein expression compatible with the corresponding histologic subtypes, such as CK in the epithelioid subtype and SMA in the fibroblastic subtype. Thus, canine skeletal OS is composed of pleomorphic and heterogenous tumor cells as is reflected in the diversity of histologic patterns and expression of cytoskeletal proteins.

Keywords

canine osteosarcoma cytoskeleton pleomorphism head appendicular immunohistochemistry

Osteosarcoma (OS) is the most common primary malignant bone neoplasm of dogs,^39,41 and it shows aggressive local invasiveness and highly metastatic behavior.⁵ Several clinical and histologic criteria have been reported as prognostic factors, including breed, tumor location, metastases to the lungs, completeness of surgical margins, adjuvant chemotherapy, and histologic subtype.* Between 20% and 25% of canine skeletal OS originates from bones of the axial skeleton.⁴¹ Of these, approximately 50% of axial skeletal OS occurs in the head and 50% in the ribs, vertebrae, and pelvis.⁴¹ OS of the head (OSH) is a comparatively rare tumor that has been reported in the mandible, maxilla, skull, and paranasal sinuses in dogs.⁴¹ The appendicular skeleton is affected 3 to 4 times more often than the axial skeleton and most often in the metaphyseal region of long bones.⁴¹ The proximal humerus and the distal radius in the forelimb—along with the distal femur, proximal tibia, and distal tibia in the hindlimb—are the common sites of OS of the appendicular skeleton (OSA).⁴¹

OS within the medullary cavity of bone is histologically classified into conventional OS, telangiectatic OS, small cell OS, and low-grade central OS, according to the WHO Classification of Tumours of Soft Tissue and Bone in human medicine.^17,31,33 Conventional OS has a broad spectrum of morphology and is divided into 8 histologic subtypes: osteoblastic, chondroblastic, fibroblastic, giant cell-rich, osteoblastoma-like, epithelioid, clear cell, and chondroblastic.³³ Many immunohistochemical examinations have been performed to characterize human OS. OS has a broad immunoprofile that lacks diagnostic specificity, and the commonly expressed antigens include osteocalcin, osteonectin, S-100 protein, actin, α-smooth muscle actin (SMA), neuron-specific enolase, and CD99.³³ Importantly, as it is a diagnostic pitfall, OS may also express cytokeratin (CK) and EMA detected using immunohistochemistry.³³

OS is defined as a primary malignant bone tumor that arises in the medullary cavity, with production of osteoid and/or immature bone by malignant osteoblasts.^39,41 Canine OS shows various morphologies and arrangements of neoplastic cells, and it is divided into 6 histologic subtypes according to the World Health Organization’s histologic classification of tumors of domestic animals: osteoblastic, chondroblastic, fibroblastic, telangiectatic, giant cell, and poorly differentiated.³⁹ These subtypes are frequently mixed in the same neoplasm.⁴¹ Immunohistochemical studies of canine OS using antibodies for p53, β-catenin, survivin, heat shock protein, epidermal growth factor receptor, and COX-2 have been performed to try to identify prognostic markers.^{4,25,26,36
–38,40} However, no immunohistochemical analysis of cytoskeletal elements with correlation of the results to histologic subtype has been done for canine OS.

For this study, the histologic classification system of canine skeletal OS was compared to the clinical outcome. Also, we determined whether there was an association between the histologic subtypes of canine OS and immunohistochemical expression of the cytoskeletal proteins CK, vimentin, SMA, desmin, glial fibrillary acidic protein (GFAP), and neurofilament (NF).

Material and Methods

Animals and Clinical Data

Biopsy were collected from 120 dogs (60 OSH and 60 OSA). Clinical data of these dogs were evaluated, including age, sex, breed, and affected bone. Of these 120 dogs, 95 were lost to follow-up, and a definite date of death was obtained for the remaining 25 dogs. These dogs, including 12 with OSH and 13 with OSA, were used to calculate the survival times, and were evaluated for metastases, chemotherapy, surgical margin, and histologic subtype.

Histology

Biopsy samples were removed by mandibulectomy, maxillectomy, limb amputation surgery, incisional biopsy, and needle biopsy. They were fixed in 10% neutral formalin, embedded in paraffin, cut at 4-µm thickness, and stained with hematoxylin and eosin. The neoplasms, including osseous tissues, were decalcified using 10% formic acid after fixation.

Immunohistochemistry

Histologic sections of OS were immunohistochemically examined using the avidin-biotin-peroxidase complex (ABC) procedure (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA) on paraffin sections. To remove endogenous peroxidase, sections were immersed in 0.5% periodic acid solution at room temperature for 10 minutes. The sections were incubated with primary antibodies at 4°C for 16 hours, with biotinylated secondary antibody for 30 minutes at room temperature, and with ABC for an additional 30 minutes at room temperature. Visualization was accomplished using 0.05% 3,3′-diaminobenzidine solution. Mayer’s hematoxylin stain was used as a counterstain. Details of primary antibodies used in the present study are summarized in Supplemental Table 1. Immunoreactivity of the neoplasm cells was classified into 4 grades, according to whether 0%, 1%–25%, 26%–50%, or 51%–100% of neoplastic cells showed immunolabeling (allocated scores of 0, 1, 2, and 3, respectively).

Statistical Analysis

The survival times and prevalence of pulmonary metastasis were compared between OSH and OSA using the Kaplan Meier method, log-rank test, χ² test, and Fisher exact probability test. The prognostic significance of chemotherapy and surgical margins were analyzed using the Kaplan-Meier method. The association between the survival times or pulmonary metastasis and the frequency of each histologic subtype was investigated using the Kaplan Meier method, log-rank test, χ² test, and Fisher exact probability test.

The proportions of each subtype between OSH and OSA were compared using the χ² test or Fisher exact probability test. Spearman rank correlation coefficient by rank test was used to investigate the potential correlation among the immunoreactivity scores of each of the cytoskeletal proteins. Also, immunoreactivity scores from each cytoskeletal protein among subtypes were compared using the Kruskal-Wallis test and Mann–Whitney U test. Furthermore, the relationships of immunoreactivity of each cytoskeletal protein between OSH and OSA were compared using the Mann–Whitney U test. A P value <0.05 was considered statistically significant.

Results

Clinical Data

The mean age of the dogs examined was 10 years (range, 6 weeks–18 years). There was a female:male ratio of 1.1:1, including 63 females and 57 males. Thirty breeds were represented, the most common ones being mongrels (31%), Golden Retrievers (13%) and Labrador Retrievers (10%). In the OSH cases, tumors were in the maxilla (22%), mandible (47%), and zygomatic bone (3%), while in the appendicular cases, OSA were in the scapula (15%), humerus (27%), radius (2%), ulna (5%), carpal bones (3%), phalanges of the manus (3%), femur (12%), and tibia (2%).

The survival data of 25 dogs, including 12 with OSH and 13 with OSA, are summarized in Supplemental Tables 2 and 3. The median ST of OSH was 525 days (range, 117–1486 days), and that of OSA was 238 days (range, 40–466). Metastases to the lungs were observed in 2 OSH and 10 OSA. Seven dogs received adjuvant chemotherapy using carboplatin, and the surgical margins of 3 dogs were dirty (1 OSH, 2 OSA).

Histologic Findings

The neoplasms were classified into 6 subtypes depending on the histologic classification of domestic animals. In some OSH and OSA cases, the neoplasms could not be classified into any of these 6 types, but were instead subclassified into myxoid, round cell, and epithelioid subtypes. Although the classification of subtype was determined depending on the predominant histologic findings, the neoplasms were categorized as a mixed subtype if multiple subtypes were present and a single subtype was not predominant. The frequency of the histologic subtypes of OSH and OSA is summarized in Supplemental Table 4.

In OSH, the neoplasms were composed of very pleomorphic tumor cells, and 63% of neoplasms were categorized as mixed subtypes since they contained multiple histologic subtypes. In the osteoblastic subtypes found in 45 OSH, the polyhedral to spindle tumor cells produced osteoid with calcification and formation of immature bone trabeculae (Fig. 1). In the chondroblastic subtypes found in 15 OSH, the polyhedral tumor cells produced hyaline cartilage (Fig. 2). In the fibroblastic subtypes found in 20 OSH, the spindle-shaped tumor cells were arranged in a wavelike fashion or a storiform pattern (Fig. 3). In the telangiectatic subtypes found in 16 OSH, the polyhedral tumor cells formed many large or small, blood-filled or empty cystic spaces, and the septa exhibited a variable thickness (Fig. 4). In the giant cell subtypes found in 14 OSH, the aggregated nests of multinucleate giant cells were sporadically present, mixed in with the components of other subtypes (Fig. 5). In the poorly differentiated subtypes found in 7 OSH, the neoplasms consisted of malignant mesenchymal cells exhibiting various morphologies, such as large pleomorphic cells and small cells resembling the reticular cells of bone marrow (Fig. 6). In the myxoid subtypes found in 6 OSH, the spindle-shaped tumor cells were loosely arranged in an abundant myxoid matrix (Fig. 7). In the round cell subtypes found in 6 OSH, the neoplasms consisted of round tumor cells with scant cytoplasms and round to oval nuclei, and the tumor cells proliferated in a sheet with the production of lacelike osteoid (Fig. 8). In the epithelioid subtypes found in 5 OSH, the tumor cells showed cytologic features such as large polyhedral morphology, a large nucleus, abundant eosinophilic cytoplasm, and shhet-like arrangment of cells (Fig. 9).

Figure 1. Osteoblastic subtype osteosarcoma (OS). Mandible; dog. Polyhedral or spindle tumor cells produce osteoid and form immature bone trabeculae. Hematoxylin and eosin (HE). Figure 2. Chondroblastic subtype OS. Humerus; dog. Polyhedral or spindle tumor cells produce chondroid matrices and form cartilaginous tissue. HE. Figure 3. Fibroblastic subtype OS. Mandible; dog. Spindle-shaped tumor cells have elongated or oval nuclei that are arranged in a wavelike fashion. HE. Figure 4. Telangiectatic subtype OS. Mandible; dog. Polyhedral or spindle tumor cells form many blood-filled cysts, produce osteoid with calcification, and form osteocartilaginous tissues. HE. Figure 5. Giant cell subtype OS. Mandible; dog. Multinucleate giant cells are sporadically present in the osteoblastic subtype. HE. Figure 6. Poorly differentiated subtype OS. Humerus; dog. Pleomorphic tumor cells with large atypical nuclei proliferate with the production of little osteoid. HE. Figure 7. Myxoid subtype OS. Mandible; dog. Spindle-shaped tumor cells are loosely arranged in abundant myxoid matrices. HE. Figure 8. Round cell subtype OS. Humerus; dog. Small round tumor cells with scanty cytoplasms and round nuclei proliferate in a sheet with the production of osteoid. HE. Figure 9. Epithelioid subtype OS. Mandible; dog. Large polyhedral tumor cells with abundant eosinophilic cytoplasms are arranged in a sheet. HE.

In OSA, 65% of neoplasms were categorized as mixed subtypes since they contained multiple histologic subtypes as with OSH. Subtypes observed in OSA included osteoblastic (n = 44), chondroblastic (n = 16), fibroblastic (n = 20), telangiectatic (n = 16), giant cell (n = 13), poorly differentiated (n = 7), myxoid (n = 3), and round cell (n = 8). The epithelioid subtype was not detected in OSA. The histologic features of each subtype of OSA were similar to those of OSH (Fig. 1–8), and significant differences in the frequency of each subtype were not observed between OSH and OSA.

In 25 dogs in which the survival data were available, 7 subtypes were found in OSH—including osteoblastic (n = 11), chondroblastic (n = 3), fibroblastic (n = 6), telangiectatic (n = 1), poorly differentiated (n = 1), myxoid (n = 1), and epithelioid (n = 1)—while 6 subtypes were found in OSA: osteoblastic (n = 11), chondroblastic (n = 6), fibroblastic (n = 6), telangiectatic (n = 1), poorly differentiated (n = 4), and myxoid (n = 1).

Immunohistochemical Findings

Both OSH and OSA showed various relationships between hitologic subtypes and immunohistochemical detection of cytoskeletal proteins. Immunohistochemical results of the OSH and OSA are summarized in Table 1.

Table 1.

Expression of Cytoskeletal Proteins for Each Subtype of Osteosarcoma (Percentage of Cases).

Subtype	Osteosarcoma of the Head^a					Osteosarcoma of the Appendicular Skeleton^a
Subtype	CK	SMA	Desmin	GFAP	NF	CK	SMA	Desmin	GFAP	NF
Osteoblastic	27	71	0	15	7	18	57	4	25	18
Chondroblastic	0	33	0	20	7	19	20	0	40	27
Fibroblastic	20	85	5	20	0	11	68	0	5	11
Telangiectatic	13	94	6	12	6	7	80	7	20	7
Giant cell	0	21	0	0	0	0	0	0	0	0
Poorly differentiated	14	43	0	28	0	0	55	9	9	9
Myxoid	0	84	17	0	0	0	77	0	67	0
Round cell	0	17	17	34	0	13	50	0	13	13
Epithelioid	60	80	0	0	0	n/a	n/a	n/a	n/a	n/a

Abbreviation: CK, cytokeratin; SMA, α-smooth muscle actin; GFAP, glial fibrillary acidic protein; NF, neurofilament; n/a, not applicable.

^aVimentin: 100% for each subtype.

In OSH, CK-positive tumor cells were present in 27% of osteoblastic (Fig. 10a), 20% of fibroblastic, 13% of telangiectatic, 14% of poorly differentiated, and 60% of epithelioid subtypes (Fig. 13a). All CK-positive tumor cells were immunoreactive for vimentin, and some of them were also immunoreactive for SMA (Figs. 10b, 13b). SMA-positive tumor cells were present in 71% of osteoblastic (Fig. 10b), 33% of chondroblastic, 85% of fibroblastic (Fig. 11b), 94% of telangiectatic (Fig. 12b), 21% of giant cell, 43% of poorly differentiated, 84% of myxoid, 17% of round cell, and 80% of epithelioid subtypes (Fig. 13b). Some of the SMA-positive tumor cells were also immunoreactive for desmin (Figs. 11c, 12c).

Figure 10. Osteoblastic subtype of osteosarcoma (OS). Mandible; dog. Comparison of immunoreactivity with cytoskeleton: (a) cytokeratin (CK), (b) α-smooth muscle actin, (SMA), (c) desmin. Polyhedral or spindle tumor cells show strong expression of CK and SMA. Desmin is not detected in this neoplasm. Immunohistochemistry (IHC). Figure 11. Fibroblastic subtype OS. Mandible; dog. Comparison of immunoreactivity with cytoskeleton: (a) CK, (b) SMA, (c) desmin. Spindle-shaped tumor cells show strong expression of SMA, and a few of these cells are positive for desmin. CK is not detected in this neoplasm. IHC. Figure 12. Telangiectatic subtype OS. Mandible; dog. Comparison of immunoreactivity with cytoskeleton: (a) CK, (b) SMA, (c) desmin. Polyhedral or spindle tumor cells show strong expression of SMA, and some of these cells are positive for desmin. CK is not detected in this neoplasm. IHC. Figure 13. Epithelioid subtype OS. Mandible; dog. Comparison of immunoreactivity with cytoskeleton: (a) CK, (b) SMA, (c) desmin. Epithelioid tumor cells show strong expression of CK and SMA. Desmin is not detected in this neoplasm. IHC.

In OSA, GFAP-positive tumor cells were present in 25% of osteoblastic, 40% of chondroblastic, 5% of fibroblastic, 20% of telangiectatic, 9% of poorly differentiated, 67% of myxoid, and 13% of round cell subtypes. Some of the GFAP-positive tumor cells were also immunoreactive for NF. NF-positive tumor cells were present in 18% of osteoblastic, 27% of chondroblastic, 11% of fibroblastic, 7% of telangiectatic, 9% of poorly differentiated, and 13% of round cell subtypes.

Statistical Analysis

The survival times of OSH were significantly longer than those of OSA (P < 0.05), and prevalence of pulmonary metastasis was significantly higher for OSA than for OSH (P < 0.05). The survival times were not different regardless of whether chemotherapy was received or surgical margins were dirty (P > 0.05). No significant association was observed between the survival times or prevalence of pulmonary metastasis and the frequency of each histologic subtype (P > 0.05).

Although no significant difference between OSH and OSA was observed in the frequency of each histologic subtype (P > 0.05), the epithelioid subtype was detected only in OSH. Immunoreactivity for CK was significantly stronger for, the osteoblastic and epithelioid subtypes than for other subtypes (P < 0.05). Immunoreactivity for SMA was significantly stronger for the fibroblastic and telangiectatic subtypes than for other subtypes (P < 0.05), and the immunoreactivity of SMA of OSH was significantly stronger than SMA of OSA (P < 0.05). For cytoskeletal proteins other than CK and SMA, a significant difference in immunoreactivity was not observed among subtypes (P > 0.05). Also, except for SMA, significant differences in immunoreactivity for cytoskeletal proteins between OSH and OSA (P > 0.05). The immunoreactivity of NF and GFAP was significantly correlated (P < 0.05).

Discussion

The clinical data, including the age, sex, and breed, were comparable to those of previous studies.^{11,20,23,24,27,41} The mandible was affected more than twice as often as the maxilla in OSH. Although the prevalence in the scapula and humerus was higher than in previous studies, the prevalence in the ulna and radius was lower.^{16,20,21,27,41} Significant differences of the survival times and the frequency of pulmonary metastasis indicate that OSH shows a better prognosis than OSA. This finding supports previous studies that the survival times or metastases with OS of the axial skeleton are marginally better than those with appendicular tumors.^11,16,24,41

Canine skeletal OS, including OSH and OSA, were composed of pleomorphic and heterogenous tumor cells, and 64% of OSH and OSA contained multiple histologic subtypes in the same neoplasm. The mixed subtypes were more frequent than those of the previous studies.^{11,20,23,24,27} Canine skeletal OS is considered to originate from multipotential mesenchymal cells in the medullary cavity, and these results suggest that this origin leads to its histologic diversity and heterogeneity. A significant difference between OSH and OSA in the proportion of each subtype was not observed indicating that canine skeletal OS may have diverse morphology regardless of the involved bone.

No correlation was observed between the survival times or prevalence of pulmonary metastasis and the frequency of each histologic subtype. Although several previous studies reported that fibroblastic OS has a relatively favorable prognosis and the telangiectatic OS has a very poor prognosis,^11,27 other studies including the present study concluded that the histologic subtypes were not associated with prognosis.^20,23 To evaluate the usefulness of histologic classification as a prognostic indicator for canine OS, the accumulation of data from large numbers of cases and the construction of new histologic classification system that evaluates the mixed subtype and the new subtypes may be warranted.

We classified 3 histologic subtypes—myxoid, round cell, and epithelioid—in addition to the subtypes previously used in domestic animals. The myxoid subtype was not observed as a component of chondroblastic OS, but instead was a predominant histologic subtype. This finding does not concur with previous reports that the myxoid morphology occasionally appears in a part of chondroblastic OS in humans.³³ The round cell subtype consisted of small round tumor cells similar to those described in a report of canine small cell osteogenic sarcoma.¹⁰ Some OSH exhibited epithelioid features in the present study. In human medicine, small cell and epithelioid OS have been classified on the basis of their histologic features but these have not been described in canine OS.^17,33 Although it will be necessary to study more of these cases, we consider that the myxoid, round cell, and epithelioid subtypes should be distinguished as separate histologic subtypes in canine skeletal OS, because they exhibited predominant histologic features in some neoplasms.

Immunohistochemically, although the intermediate filaments have been popularly known as useful markers to understand the property of tumor cells and to diagnose their origin, some neoplasms show relationships between patterns of intermediate filament expression and histologic patterns. In general, intratumor heterogeneity –in which neoplasms consist of areas with different phenotypes–has been recognized for many years.⁹ In the present study of canine skeletal OS, the expression of various cytoskeletal proteins including CK, vimentin, SMA, desmin, GFAP, and NF had some conformity with histologic morphology. We consider that these immunohistochemical characteristics are attributable to tumor heterogeneity of canine skeletal OS.

The tumor cells of both OSH and OSA showed expression of CK in the osteoblastic, chondroblastic, fibroblastic, telangiectatic, poorly differentiated, and round cell subtypes, but CK expression was especially prevalent in the epithelioid subtype. All CK-positive tumor cells coexpressed vimentin. These results revealed that epithelioid tumor cells have a tendency to express CK, but retain expression of mesenchymal cytoskeletal protein (vimentin). Recently, there have been several case reports of epithelioid OS in human medicine, with or without the expression of CK.^† Okada et al reported that the expression of CK had been observed in some tumor cells of osteoblastic, chondroblastic, and fibroblastic OS with epithelioid features.²⁹ Hasegawa et al reported that osteoblastic and epithelioid OS showed the coexpression of CK and vimentin.^12,13 These reports support the view that canine OS also has the potential to exhibit epithelioid morphology and express CK. Furthermore, the results of the present study suggest that canine OS shows more histologic and immunohistochemical diversity than human OS. Specifically, unlike human OS, CK expression was detected in various histologic subtypes of canine OS including poorly differentiated and telangiectatic subtypes. To the best of our knowledge, the present study is the first report of canine skeletal OS with an epithelioid morphology and with expression of CK.

SMA-positive tumor cells were observed in all subtypes. In particular, the fibroblastic and telangiectatic tumor cells showed significantly stronger immunoreactivity for SMA than other subtypes, and OSH exhibited significantly stronger immunoreactivity for SMA than OSA. A few desmin-positive tumor cells were observed in the osteoblastic, fibroblastic, telangiectatic, poorly differentiated, and myxoid subtypes, and these tumor cells correspondingly showed immunoreactivity for SMA. Most SMA-and desmin-positive tumor cells exhibited a spindle-shaped and fibroblast-like morphology, and some of them showed the expression of CK and vimentin. Although it has been reported that OS with various histologic subtypes had immunoreactivity for SMA and desmin in human medicine,^13,15,42 statistical analysis concerning the correlation between the expression of cytoskeletal proteins and its histologic subtype has not been performed. The results of the present study suggest that SMA- and desmin-positive tumor cells, especially those of the fibroblastic and telangiectatic subtypes of OSH, have the property of myofibroblasts or smooth muscle cells. Although it is unclear why SMA expression of OSH was stronger than OSA, the difference in the origin of the primary bone of OS may be one of the factors.

GFAP-positive tumor cells were observed not only in the osteoblastic and chondroblastic subtypes but also in fibroblastic, telangiectatic, poorly differentiated, myxoid, and round cell subtypes. In addition, NF-positive tumor cells were observed in osteoblastic, chondroblastic, fibroblastic, telangiectatic, poorly differentiated, and round cell subtypes. Kasantikul and Shuangshoti reported that, in humans, mature osteocytes and chondrocytes had cytoskeletal intermediate filaments identical to or associated with GFAP.¹⁸ Also, osteoblast-like tumor cells reportedly showed immunoreactivity for GFAP in human gliosarcoma with differentiation of osteoblastic and chondroblastic OS,^1,2 while human osteoblastic and chondroblastic OS exhibited expression of GFAP.³⁵ OS with the expression of NF has not been reported in both humans and dogs. The present study revealed that GFAP was preserved in canine OS not only with osteocartilaginous differentiation but also with other histologic morphologies.

In conclusion, canine skeletal OS is composed of highly pleomorphic and heterogenous tumor cells, and frequently shows various histologic subtypes in the same neoplasm. Some are of myxoid, round cell, or epithelioid subtype that are not included in the current classification of OS in domestic animals. Histologic classification into subtypes does not appear to be a useful prognostic indicator. No significant difference was observed between OSH and OSA with respect to the proportion of each subtype or the expression of cytoskeletal proteins other than SMA. The heterogeneity of canine skeletal OS is reflected in their expression of various cytokeletal proteins, and the potential to differentiate into epithelioid cells and various mesenchymal cells such as myofibroblasts and smooth muscle cells.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Supplemental material for this article is available on the Veterinary Pathology website at .

Notes

References

Barresi

Cerasoli

Morigi

Cremonini

Volpini

Tuccari

. Gliosarcoma with features of osteoblastic osteosarcoma: a review. Arch Pathol Lab Med. 2006;130:1208–1211.

Barut

Kandemir

Ozdamar

. Gliosarcoma with chondroblastic osteosarcomatous differentation: report of two case with clinicopathologic and immunohistochemical features. Turk Neurosurg. 2009;19:417–422.

Boerman

Selvarajah

Nielen

Kirpensteijn

. Prognostic factors in canine appendicular osteosarcoma: a meta-analysis. BMC Vet Res. 2012;8:56.

Bongiovanni

Mazzocchetti

Malatesta

. Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma. BMC Vet Res. 2012;8:78.

Brodey

Riser

. Canine osteosarcoma: a clinicopathologic study of 194 cases. Clin Orthop Relat Res. 1969;62:54–64.

Carlos-Bregni

Contreras

Hiraki

Vargas

Leon

de Almeida

. Epithelioid osteosarcoma of the mandible: a rare case with unusual immunoprofile. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:47–52.

Cohen

Reif

Brodey

Keiser

. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res. 1974;34:2859–2868.

Dernell

Straw

Cooper

Powers

LaRue

Withrow

. Multilobular osteochondrosarcoma in 39 dogs: 1979–1993. J Am Anim Hosp Assoc. 1998;34:11–18.

Dexter

Kowaiski

Blazar

Fligiel

Vogel

Heppner

. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978;38:3174–3181.

10.

Frazier

Herron

Dee

Ghandur-Mnymneh

Altman

. Development of small-cell osteogenic sarcoma after ulnar ostectomy in a dog. J Am Vet Med Assoc. 1991;198:432–434.

11.

Hammer

Weeren

Weisbrode

Padgett

. Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. J Am Anim Hosp Assoc. 1995;31:321–326.

12.

Hasegawa

Hirose

Kudo

Hizawa

Usui

Ishi

. Immunophenotypic heterogeneity in osteosarcomas. Hum Pathol. 1991;22:583–590.

13.

Hasegawa

Hirose

Seki

Hizawa

Ishii

Wakabayashi

. Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas. Cancer Detect Prev. 1997;21:280–287.

14.

Hasegawa

Shibata

Hirose

Seki

Hizawa

. Osteosarcoma with epithelioid features: an immunohistochemical study. Arch Pathol Lab Med. 1993;117:295–298.

15.

Hemingway

Kashima

Mahendra

. Smooth muscle actin expression in primary bone tumors. Virchows Arch. 2012;460:525–534.

16.

Heyman

Diefenderfer

Goldschmidt

Newton

. Canine axial skeletal osteosarcoma: a retrospective study of 116 cases (1986 to 1989). Vet Surg. 1992;21:304–310.

17.

Kalil

Squire

. Small cell osteosarcoma. In: Fletcher

CDM

Bridge

Hogendoorn

PCW

Mertens

, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013:291.

18.

Kasantikul

Shuangshoti

. Positivity to glial fibrillary acidic protein in bone, cartilage, and chordoma. J Surg Oncol. 1989;41:22–26.

19.

Kaveri

Rekha

Punnya

. Epithelioid osteosarcoma of the maxilla: report of an unusual case. Br J Oral Maxillofac Surg. 2009;47:143–145.

20.

Kirpensteijn

Kik

Rutteman

Teske

. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol. 2002;39:240–246.

21.

Knecht

Priester

. Musculoskeletal tumors in dogs. J Am Vet Med Assoc. 1978;172:72–74.

22.

Kramer

Hicks

Palis

. Epithelioid osteosarcoma of bone: immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm. Cancer. 1993;71:2977–2982.

23.

Kruse

Holmes

Balko

Fernandez

Brown

Goldschmidt

. Evaluation of clinical and histopathologic prognostic factors for survival in canine osteosarcoma of the extracranial flat and irregular bones. Vet Pathol. 2012;50:704–708.

24.

Loukopoulos

Robinson

. Clinicopathological relevance of tumour grading in canine osteosarcoma. J Comp Pathol. 2007;136:65–73.

25.

Loukopoulos

Thornton

Robinson

. Clinical and pathologic relevance of p53 index in canine osseous tumors. Vet Pathol. 2003;40:237–248.

26.

Millanta

Asproni

Cancedda

Vignoli

Bacci

Poli

. Immunohistochemical expression of COX-2, mPGES and EP2 receptor in normal and reactive canine bone and in canine osteosarcoma. J Comp Pathol. 2012;147:153–160.

27.

Misdrop

Hart

. Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst. 1979;62:537–545.

28.

Okada

Hasegawa

Yokoyama

. Rosette-forming epithelioid osteosarcoma: a histologic subtype with highly aggressive clinical behavior. Hum Pathol. 2001;32:726–733.

29.

Okada

Hasegawa

Yokoyama

Beppu

Itoi

. Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol. 2003;56:742–746.

30.

Okada

Hasegawa

Yokoyama

Beppu

Itoi

. Prognostic relevance of rosette-like features in osteosarcoma. J Clin Pathol. 2003;56:831–834.

31.

Oliveira

Okada

Squire

. Telangiectatic osteosarcoma. In: Fletcher

CDM

Bridge

Hogendoorn

PCW

Mertens

, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013:289–290.

32.

Rinaggio

Kewitt

McGuff

. Epithelioid osteosarcoma presenting as a rapidly expanding maxillary mass. Head Neck. 2007;29:705–709.

33.

Rosenberg

Cleton-Jansen

A-M

de Pinieux

Deyrup

Hauben

Squire

. Conventional osteosarcoma. In: Fletcher

CDM

Bridge

Hogendoorn

PCW

Mertens

, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013:282–288.

34.

Terracini

Glickman

. Host related risk factors for canine osteosarcoma. Vet J. 1998;156:31–39.

35.

Santos

Carvalho

Falzoni

. Glial fibrillary acidic protein in tumor types with cartilaginous differentiation. Mod Pathol. 2009;22:1321–1327.

36.

Selvarajah

Bonestroo

Kirpensteijn

. Heat shock protein expression analysis in canine osteosarcoma reveals HSP60 as a potentially relevant therapeutic target. Cell Stress Chaperones. 2013;18:607–622.

37.

Selvarajah

Verheije

Kik

. Expression of epidermal growth factor receptor in canine osteosarcoma: association with clinicopathological parameters and prognosis. Vet J. 2012;193:412–419.

38.

Shoeneman

Ehrhart

3rd Eickhoff

Charles

Powers

Thamm

. Expression and function of survivin in canine osteosarcoma. Cancer Res. 2012;72:249–259.

39.

Slayter

Boosinger

Pool

Dammrich

Misdrop

Larsen

World Health Organization, International Histologic Classification of Tumors of Domestic Animals, Histological Classification of Bone and Joint Tumors of Domestic Animals. 2nd series. Vol 1. Washington, DC: Armed Forces Institute of Pathology American Registry of Pathology; 1994.

40.

Stein

Holmes

Muthuswamy

Thompson

Huelsmeyer

. Characterization of β-catenin expression in canine osteosarcoma. Vet Comp Oncol. 2011;9:65–73.

41.

Thompson

Pool

. Tumors of bones. In: Mueten

, ed. Tumors in Domestic Animals. 4th ed. Ames, IA: Iowa State Press; 2002:245–317.

42.

Yamamura

Yoshikawa

Tatsuta

Akedo

Takahashi

. Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer. 1998;79:245–250.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.07 MB

0.00 MB

Diversity of Histologic Patterns and Expression of Cytoskeletal Proteins in Canine Skeletal Osteosarcoma

Abstract

Keywords

Material and Methods

Animals and Clinical Data

Histology

Immunohistochemistry

Statistical Analysis

Results

Clinical Data

Histologic Findings

Immunohistochemical Findings

Statistical Analysis

Discussion

Footnotes

Declaration of Conflicting Interests

Funding

Notes

References

Supplementary Material